Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.1 Thousand DKK | 70.09% |
| 2022 | -40.45 Million USD | -305.01% |
| 2021 | -603.91 Million DKK | 89.93% |
| 2020 | -603.44 Million DKK | -98.77% |
| 2019 | -331.91 Million DKK | 78.33% |
| 2018 | -230.28 Million DKK | -76.74% |
| 2017 | -130.29 Million DKK | -107.43% |
| 2016 | -62.94 Million DKK | -19.58% |
| 2015 | -58.47 Million DKK | -43.12% |
| 2014 | -36.7 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 264.81 Thousand USD | 1848100.0% |
| 2023 FY | - DKK | 33.16% |
| 2023 Q2 | -1.87 Million USD | 0.0% |
| 2023 Q4 | -2.1 Million USD | 0.0% |
| 2022 FY | - USD | -305.01% |
| 2022 Q4 | -1.73 Million USD | 0.0% |
| 2022 Q2 | -3.83 Million USD | 0.0% |
| 2021 FY | - DKK | 89.93% |
| 2020 FY | - DKK | -98.77% |
| 2019 FY | - DKK | 78.33% |
| 2018 FY | - DKK | -76.74% |
| 2017 FY | - DKK | -107.43% |
| 2016 FY | - DKK | -19.58% |
| 2015 FY | - DKK | -43.12% |
| 2014 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.983% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.796% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.981% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.93% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.013% |
| Mesoblast Limited | -62.38 Million USD | 99.981% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 99.212% |
| Genus plc | 73.7 Million USD | 100.016% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.817% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 99.659% |
| Marizyme, Inc. | -34.28 Million USD | 99.965% |
| ContraFect Corporation | -64.99 Million USD | 99.981% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.862% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.733% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 99.137% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 99.542% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 99.479% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 97.664% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.677% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.975% |
| EV Biologics, Inc. | -1.26 Million USD | 99.045% |
| Q BioMed Inc. | -617.62 Thousand USD | 98.041% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.339% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 98.086% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 99.47% |
| Biomind Labs Inc. | -1.03 Million USD | 98.83% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.123% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.831% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.911% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 99.186% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 51.592% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 99.688% |
| IMV Inc. | -35.52 Million USD | 99.966% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.924% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 99.516% |
| GB Sciences, Inc. | -1.41 Million USD | 99.148% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.875% |
| HST Global, Inc. | -5303.00 USD | -128.21% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 83.707% |
| Enzolytics Inc. | -2.12 Million USD | 99.43% |
| Resverlogix Corp. | -11.74 Million USD | 99.897% |
| Affymax, Inc. | -14.29 Million USD | 99.915% |
| SYBLEU INC | -141.57 Thousand USD | 91.452% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 99.605% |
| argenx SE | -216.02 Million USD | 99.994% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.978% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.994% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 99.193% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 103.194% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.802% |
| Zenith Capital Corp. | -8.6 Million USD | 99.859% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.995% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 30.532% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 99.505% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 93.125% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.969% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 99.582% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 98.843% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 279.982% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 99.308% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 99.37% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.84% |
| ONE Bio Corp. | 13.61 Million USD | 100.089% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 93.317% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 99.412% |
| Agentix Corp. | -1.37 Million USD | 99.118% |
| LadRx Corporation | 412.28 Thousand USD | 102.935% |
| Cell Source, Inc. | -4.27 Million USD | 99.717% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 96.704% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.826% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 98.708% |
| NovAccess Global Inc. | -1.03 Million USD | 98.83% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.137% |
| Itoco Inc. | -1.86 Million USD | 99.352% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 96.812% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 98.916% |
| Kadimastem Ltd | -2.62 Million USD | 99.539% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 94.94% |
| CytoDyn Inc. | -18.02 Million USD | 99.933% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 84.687% |
| Mobile Lads Corp. | -2.24 Million USD | 99.46% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 1.039% |
| Qrons Inc. | -40.08 Thousand USD | 69.806% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 97.508% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 102.295% |
| Rebus Holdings, Inc. | -951 Thousand USD | 98.727% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 98.86% |
| International Stem Cell Corporation | 202 Thousand USD | 105.991% |
| Bioxytran, Inc. | -3.82 Million USD | 99.683% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 77.01% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 99.508% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.966% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | 73.107% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 99.558% |
| Neutra Corp. | -181.24 Thousand USD | 93.323% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.94% |
| PureTech Health plc | -11.62 Million USD | 99.896% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.94% |
| IXICO plc | -707 Thousand USD | 98.288% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.843% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.975% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 99.987% |